SLDB
NASDAQSolid Biosciences Inc.
Price$5.55-0.20 (-3.48%)
01:30 PM07:45 PM
News · 26 weeks36+50%
2026-04-192026-10-11
Mix1390d
- Other5(38%)
- SEC Filings4(31%)
- Analyst3(23%)
- Insider1(8%)
Latest news
25 items- ANALYSTUBS initiated coverage on Solid Biosciences with a new price targetUBS initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $20.00
- INSIDERSEC Form 4 filed by Solid Biosciences Inc.4 - Solid Biosciences Inc. (0001707502) (Issuer)
- PRSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement
- ANALYSTRBC Capital Mkts initiated coverage on Solid Biosciences with a new price targetRBC Capital Mkts initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $18.00
- PRSolid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare ConferenceBo Cumbo, President and CEO, and Gabriel Books, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, September 9, 2026, at 3:55 p.m. ET. A live webcast of the presentation will be available by clicking here. 2026 Citi Biopharma Back to School ConferenceMr. Cumbo and Dr. Brooks will participate in a fireside chat on Thursday, September 1
- ANALYSTTruist resumed coverage on Solid Biosciences with a new price targetTruist resumed coverage of Solid Biosciences with a rating of Buy and set a new price target of $20.00
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.SCHEDULE 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
- SECSEC Form 8-K filed by Solid Biosciences Inc.8-K - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form 424B5 filed by Solid Biosciences Inc.424B5 - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form S-3ASR filed by Solid Biosciences Inc.S-3ASR - Solid Biosciences Inc. (0001707502) (Filer)
- PRSolid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 - - Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 - - Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in Q2 2026 - - Friedreich’s Ataxia (SGT-212): Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical trial; SGT-212 has been well tolerated in the two participants dosed as of August 4, 2026 - - Capital P
- SECSEC Form 10-Q filed by Solid Biosciences Inc.10-Q - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form SCHEDULE 13G filed by Solid Biosciences Inc.SCHEDULE 13G - Solid Biosciences Inc. (0001707502) (Subject)
- INSIDERDirector Smith Ian F converted options into 3,440 shares, increasing direct ownership by 3% to 138,145 units (SEC Form 4)4 - Solid Biosciences Inc. (0001707502) (Issuer)
- INSIDERNew insider Ra Capital Management, L.P. claimed ownership of 12,036,126 shares (SEC Form 3)3 - Solid Biosciences Inc. (0001707502) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.SCHEDULE 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
- INSIDERSEC Form 4 filed by Director Stone Adam Leo4 - Solid Biosciences Inc. (0001707502) (Issuer)
- SECSolid Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form 424B7 filed by Solid Biosciences Inc.424B7 - Solid Biosciences Inc. (0001707502) (Filer)
- PRSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducem
- PRSolid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Jefferies Global Healthcare ConferenceBo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m. ET.A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page. Goldman Sachs 47th Annual Global Healthcare ConferenceMr. Cumbo wi
- PRSolid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program's global development - - Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 - - Friedreich's Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON clinical trial; SGT-212 has been
- SECSEC Form 10-Q filed by Solid Biosciences Inc.10-Q - Solid Biosciences Inc. (0001707502) (Filer)
- PRSolid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 - - Solid received a positive opinion from the European Medicines Agency (EMA) on its Pediatric Investigation Plan (PIP) for SGT-003, establishing alignment on a pediatric clinical development framework in Europe - - 46 participants have been dosed with SGT-003 in the Phase 1/2 INSPIRE DUCHENNE clinical trial using a steroid-only prophylactic immunomodulation regimen; SGT-003 has been generally well tolerated as of a May 4, 2026, cutoff date - CHARLESTOWN,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Solid Biosciences Inc.SCHEDULE 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
SLDB FAQ
7 questionsWhat does Solid Biosciences Inc. do?
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in...Where does SLDB stock trade?
Solid Biosciences Inc. (SLDB) is listed on NASDAQ.What sector and industry is SLDB in?
Solid Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Solid Biosciences Inc. go public?
Solid Biosciences Inc. (SLDB) completed its IPO in 2018.What are analysts saying about SLDB?
Solid Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $2000.00 price target on 2026-10-15. Recent price targets range from $1400.00 to $2600.00.What companies are similar to SLDB?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SLDB side-by-side with any of them on Quantisnow.How can I track SLDB on Quantisnow?
Quantisnow aggregates Solid Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLDB to receive live email and push alerts on every new disclosure.